Description

Novelix Pharmaceuticals Limited lists 15,45,000 new equity shares issued at Rs. 20/- on preferential basis pursuant to warrant conversion, with lock-in periods up to June 2027.

Summary

BSE has listed 15,45,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) effective November 27, 2025. These shares were issued at Rs. 20/- per share (face value Rs. 10/- plus premium of Rs. 10/-) to promoters and non-promoters on preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.

Key Points

  • Company: Novelix Pharmaceuticals Limited (Scrip Code: 536565)
  • Number of Shares: 15,45,000 equity shares of Rs. 10/- each
  • Issue Price: Rs. 20/- (including premium of Rs. 10/-)
  • Allotment Date: August 14, 2025
  • Trading Commencement: November 27, 2025
  • ISIN: INE314I01036
  • Distinctive Numbers: 12935001 to 14480000
  • Issuance Type: Preferential allotment pursuant to warrant conversion
  • Ranking: Pari-passu with existing equity shares

Regulatory Changes

No regulatory changes introduced by this circular.

Compliance Requirements

  • Trading members must note the listing of new securities for trading purposes
  • Lock-in restrictions must be observed as per specified lock-in periods
  • The shares are subject to preferential allotment regulations

Important Dates

  • Allotment Date: August 14, 2025
  • Trading Start Date: November 27, 2025
  • Lock-in Expiry (9,00,000 shares): June 30, 2027 (Dist. Nos. 12935001 to 13835000)
  • Lock-in Expiry (6,45,000 shares): June 30, 2026 (Dist. Nos. 13835001 to 14480000)

Impact Assessment

Market Impact: Low. This is a routine preferential allotment listing resulting from warrant conversion. The issuance represents capital raising activity by the company.

Lock-in Details: Out of 15,45,000 shares, 9,00,000 shares have a lock-in period until June 30, 2027 (approximately 58.25% of new shares), while 6,45,000 shares are locked-in until June 30, 2026 (approximately 41.75% of new shares). This ensures controlled entry of these shares into the market.

Investor Impact: Existing shareholders should note the dilution from the preferential allotment. The lock-in periods provide some stability by preventing immediate sale of all new shares.

Impact Justification

Routine listing of preferential shares from warrant conversion affecting a single small-cap company with limited market impact